Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
11/26/11	SEK 0.4705	-49.79%	1,44,24,697
10/26/10	SEK 0.9370	+3.31%	11,07,793
09/26/09	SEK 0.9070	-5.52%	27,02,989
08/26/08	SEK 0.9600	+6.79%	25,13,673
07/26/07	SEK 0.8990	+9.23%	25,44,746

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 09:30:00 11/09/2026 pm IST			5-day change	1st Jan Change
0.4705 ^SEK	-49.79%		-42.83%	-43.24%

11/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW

Market Cap	9.53Cr 98.4L 84.78L 80.28L 72.76L 1.37Cr 94Cr 1.37Cr 3.67Cr 48Cr 3.7Cr 3.61Cr 151.12Cr	P/E 2026 *	-1.74x	P/E 2027 *	-1.24x
Enterprise Value	7.93Cr 81.89L 70.55L 66.8L 60.55L 1.14Cr 78Cr 1.14Cr 3.05Cr 40Cr 3.08Cr 3.01Cr 125.76Cr	EV / Sales 2026 *	2.53x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
CBOE		Real-time
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time

11/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
11/09	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
11/09	Asker plunges on choppy Stockholm market	FW
11/09	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

11/09	Alzinova: Phase II study update and SEK51 rights issue	AQ
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
11/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ
11/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101	AQ
24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ

1 day	-49.79%
1 week	-42.83%
Current month	-41.19%
1 month	-53.04%
3 months	-3.19%
6 months	-48.69%
Current year	-43.24%

1 week	0.47	1.04
1 month	0.47	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-49.79%	-42.83%	-62.24%	-85.32%	98.4L
LONZA GROUP AG	+0.79%	-6.35%	-2.99%	+9.37%	4.55TCr
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+520.30%	4.37TCr
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.85%	4.31TCr
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+73.19%	3.94TCr
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	3.19TCr
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	1.73TCr
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+108.58%	1.64TCr
EUROFINS SCIENTIFIC SE	+0.99%	-0.50%	+12.94%	+29.25%	1.42TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+36.66%	1.33TCr
Average	-4.30%	-7.16%	+49.20%	+83.63%	2.65TCr
Weighted average by Cap.	+0.69%	-3.50%	+74.68%	+124.80%

	2026 *	2027 *
Net sales	3.14Cr 32.35L 27.88L 26.4L 23.93L 44.89L 31Cr 45.11L 1.21Cr 16Cr 1.22Cr 1.19Cr 50Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.39Cr -6L -17.11L -2.23Cr -17.25L -16.87L -7.05Cr	-7.7Cr -79.47L -68.47L -64.83L -58.76L -1.1Cr -76Cr -1.11Cr -2.96Cr -39Cr -2.98Cr -2.92Cr -122.05Cr
Net Debt	-1.6Cr -16.51L -14.23L -13.47L -12.21L -22.91L -16Cr -23.02L -61.53L -8.03Cr -62.02L -60.66L -25Cr	-1.9Cr -19.61L -16.9L -16L -14.5L -27.2L -19Cr -27.34L -73.06L -9.53Cr -73.64L -72.03L -30Cr